According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $20.00 price target on Dermira and gave the company a “buy” rating in a research report on Friday, December 28th. HC Wainwright initiated coverage on Dermira in a research report on Thursday, February 14th. They issued a “buy” rating and a $13.00 price target for the company. Citigroup raised their price target on Dermira from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target (up previously from $16.00) on shares of Dermira in a research report on Monday, March 25th. Finally, BidaskClub upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Dermira has a consensus rating of “Buy” and a consensus target price of $17.36.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.75) by $0.05. Dermira had a negative return on equity of 309.23% and a negative net margin of 523.25%. On average, sell-side analysts anticipate that Dermira will post -5.25 earnings per share for the current year.
In related news, insider Eugene A. Bauer sold 35,000 shares of Dermira stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the sale, the insider now owns 43,900 shares in the company, valued at approximately $658,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 14.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Man Group plc increased its position in Dermira by 101.0% during the 3rd quarter. Man Group plc now owns 30,152 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 15,152 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Dermira in the 3rd quarter worth about $211,000. MetLife Investment Advisors LLC boosted its stake in Dermira by 55.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 10,085 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Dermira in the 3rd quarter worth about $2,871,000. Finally, Nomura Holdings Inc. boosted its stake in Dermira by 18.5% in the 4th quarter. Nomura Holdings Inc. now owns 75,696 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 11,836 shares during the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: What is a support level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.